{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:12:33Z","timestamp":1787785953341,"version":"build-2784847793"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100011775","name":"British Columbia Children\u2019s Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RE 4598\/1-2"],"award-info":[{"award-number":["RE 4598\/1-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Research BC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Palivizumab is recommended for prevention of severe respiratory syncytial virus (RSV) disease in immunocompromised children, despite a lack of strong supporting evidence. The recent approval of substitute RSV-neutralizing monoclonal antibodies against RSV, offers an opportunity to synthesize the most current evidence supporting the palivizumab standard of care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy of palivizumab in preventing acute respiratory tract infection- or RSV-related hospitalization, or mortality in immunocompromised children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched Ovid MEDLINE and EMBASE for published clinical studies that investigated outcomes of palivizumab use in children. We included clinical trials, cohort studies, and case\u2013control studies. The primary outcomes were RSV-related or respiratory viral infection-related hospitalizations, or RSV-related mortality. This systematic review was registered in PROSPERO (ID CRD42021248619) and is reported in accordance with the PRISMA guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From the 1993 records, six studies were eligible and included, for a total of 625 immunocompromised children with an heterogeneous composition of primary and acquired immunodeficiencies enrolled from palivizumab programs. There were no intervention studies. None of the studies included a control group. RSV hospitalizations were infrequent (0%\u20133.1% of children). Most children included received palivizumab, although one study (n\u2005=\u200556) did not specify how many received palivizumab. RSV mortality was neither observed, in three studies, nor reported, in three other studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The evidence supporting the use of palivizumab for prevention of severe RSV disease in immunocompromised children remains extremely limited and appears insufficient to justify prioritizing this intervention as the current standard of care over alternative interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpids\/piae004","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T15:40:35Z","timestamp":1705938035000},"page":"136-143","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of Palivizumab Immunoprophylaxis for Reducing Severe RSV Outcomes in Children with Immunodeficiencies: A Systematic Review"],"prefix":"10.1093","volume":"13","author":[{"given":"Frederic","family":"Reicherz","sequence":"first","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute , Vancouver , Canada"},{"name":"Department of Pediatrics, Faculty of Medicine, University of British Columbia , Vancouver , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahaa","family":"Abu-Raya","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute , Vancouver , Canada"},{"name":"Department of Pediatrics, Faculty of Medicine, University of British Columbia , Vancouver , Canada"},{"name":"Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre and the Nova Scotia Health Authority , Canada"},{"name":"Departments of Pediatrics, Dalhousie University , Nova Scotia , Canada"},{"name":"Microbiology and Immunology, Dalhousie University , Nova Scotia , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omolabake","family":"Akinseye","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute , Vancouver , Canada"},{"name":"Department of Pediatrics, Faculty of Medicine, University of British Columbia , Vancouver , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrad Rod","family":"Rassekh","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute , Vancouver , Canada"},{"name":"Department of Pediatrics, Faculty of Medicine, University of British Columbia , Vancouver , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew O","family":"Wiens","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia , Vancouver , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2205-0362","authenticated-orcid":false,"given":"Pascal M","family":"Lavoie","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute , Vancouver , Canada"},{"name":"Department of Pediatrics, Faculty of Medicine, University of British Columbia , Vancouver , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,27]]},"reference":[{"key":"2024022616091975300_CIT0001","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"2024022616091975300_CIT0002","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/infdis\/jiy056","article-title":"Respiratory syncytial virus seasonality: a global overview","volume":"217","author":"Obando-Pacheco","year":"2018","journal-title":"J Infect Dis"},{"key":"2024022616091975300_CIT0003","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","author":"The IMpact-RSV Study Group","year":"1998","journal-title":"Pediatrics"},{"key":"2024022616091975300_CIT0004","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"},{"key":"2024022616091975300_CIT0005","first-page":"CD013757","article-title":"Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children","volume":"11","author":"Garegnani","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2024022616091975300_CIT0006","doi-asserted-by":"crossref","first-page":"e2023061803","DOI":"10.1542\/peds.2023-061803","article-title":"Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"152","author":"Caserta","year":"2023","journal-title":"Pediatrics"},{"key":"2024022616091975300_CIT0007","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/INF.0b013e31829dff4d","article-title":"Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children","volume":"32","author":"Asner","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"2024022616091975300_CIT0008","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1097\/MPH.0000000000000086","article-title":"Respiratory syncytial virus infections in children with cancer","volume":"36","author":"Chemaly","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"key":"2024022616091975300_CIT0009","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1542\/peds.2007-1102","article-title":"Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age","volume":"121","author":"El Saleeby","year":"2008","journal-title":"Pediatrics"},{"key":"2024022616091975300_CIT0010","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1542\/peds.2014-1666","article-title":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"134","year":"2014","journal-title":"Pediatrics"},{"key":"2024022616091975300_CIT0011","article-title":"On behalf of the National Advisory Committee on Immunzation RSV Working Group","volume-title":"Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants","author":"Moore","year":"2022"},{"key":"2024022616091975300_CIT0012","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/INF.0000000000001340","article-title":"Outcomes of infants receiving palivizumab prophylaxis for respiratory syncytial virus in Canada and Italy: an international, prospective cohort study","volume":"36","author":"Manzoni","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"2024022616091975300_CIT0013","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/INF.0000000000002665","article-title":"Respiratory syncytial virus prophylaxis in immunocompromised children: outcomes from the Canadian RSV evaluation study of palivizumab registry over twelve seasons (2005\u20132017)","volume":"39","author":"Paes","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"2024022616091975300_CIT0014","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1055\/s-0041-1725146","article-title":"Respiratory syncytial virus immunoprophylaxis with palivizumab: 12-year observational study of usage and outcomes in Canada","volume":"39","author":"Mitchell","year":"2022","journal-title":"Am J Perinatol"},{"key":"2024022616091975300_CIT0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40272-017-0264-y","article-title":"Palivizumab prophylaxis against respiratory syncytial virus infection in children with immunocompromised conditions or down syndrome: a multicenter, post-marketing surveillance in Japan","volume":"20","author":"Kashiwagi","year":"2018","journal-title":"Paediatr Drugs"},{"key":"2024022616091975300_CIT0016","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1097\/INF.0000000000000392","article-title":"Palivizumab use in Japanese infants and children with immunocompromised conditions","volume":"33","author":"Mori","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2024022616091975300_CIT0017","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.bbmt.2016.07.005","article-title":"Restrictive palivizumab use does not lead to increased morbidity and mortality in pediatric hematopoietic stem cell transplantation patients","volume":"22","author":"Teusink-Cross","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024022616091975300_CIT0018","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Bmj"},{"key":"2024022616091975300_CIT0019","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.anpedi.2021.07.015","article-title":"Respiratory syncytial virus infections requiring hospitalization in patients with primary immunodeficiency","volume":"96","author":"Gonz\u00e1lez-Granado","year":"2022","journal-title":"An Pediatr (Engl Ed)"},{"key":"2024022616091975300_CIT0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12879-018-3002-3","article-title":"Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study","volume":"18","author":"Chatzis","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2024022616091975300_CIT0021","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM198607103150201","article-title":"Respiratory syncytial viral infection in children with compromised immune function","volume":"315","author":"Hall","year":"1986","journal-title":"N Engl J Med"},{"key":"2024022616091975300_CIT0022","doi-asserted-by":"crossref","first-page":"e13276","DOI":"10.1111\/tid.13276","article-title":"Respiratory syncytial virus and human metapneumovirus after allogeneic hematopoietic stem cell transplantation: impact of the immunodeficiency scoring index, viral load, and ribavirin treatment on the outcomes","volume":"22","author":"Akhmedov","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"2024022616091975300_CIT0023","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1038\/s41409-021-01462-z","article-title":"Evaluation of prognostic scores for respiratory syncytial virus infection in a French multicentre cohort of allogeneic haematopoietic stem cell transplantation recipients","volume":"56","author":"Houist","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2024022616091975300_CIT0024","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41409-022-01575-z","article-title":"Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients","volume":"57","author":"Ogimi","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2024022616091975300_CIT0025","doi-asserted-by":"crossref","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the advisory committee on immunization practices\u2014United States, 2023","volume":"72","author":"Jones","year":"2023","journal-title":"Morb Mortal Wkly Rep"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piae004\/56519747\/piae004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/13\/2\/136\/56757060\/piae004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/13\/2\/136\/56757060\/piae004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T11:09:45Z","timestamp":1708945785000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/13\/2\/136\/7590563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,27]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1,27]]},"published-print":{"date-parts":[[2024,2,26]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piae004","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,1]]},"published":{"date-parts":[[2024,1,27]]}}}